**Supplementary Table.** **Primary efficacy analysis: mean change from baseline in BCVA**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **DEX implant** | **Ranibizumab** | **p valuea** |
| ***Overall study population (n = 307)*** | | | |
| Mean change from baseline in BCVA at month 12  No. of eyes  Least-squares mean (± SE), ETDRS letters  Difference DEX-RAN (95% CI), ETDRS letters | 154 7.4 (1.0) -10.1 (-12.9, -7.2) | 153 17.4 (1.0) | 0.0006 |
| Average change in BCVA - baseline to month 3  No. of eyes  Least-squares mean (±SE), ETDRS letters  Difference DEX-RAN (95% CI), ETDRS letters | 154 10.0 (0.6) -2.8 (-4.5, -1.1) | 153 12.8 (0.6) | 0.0096 |
| Average change in BCVA - baseline to month 12  No. of eyes  Least-squares mean (± SE), ETDRS letters  Difference DEX-RAN (95% CI), ETDRS letters | 154 9.3 (0.7) -6.3 (-8.3, -4.2) | 153 15.5 (0.7) | 0.2190 |
| ***Pseudophakic eyes (*n *= 53)*** |  |  |  |
| Mean change from baseline in BCVA at month 12  No. of eyes  Least-squares mean (± SE), ETDRS letters  Difference DEX-RAN (95% CI), ETDRS letters | 26 4.4 (3.1) -7.4 (-16.0, +1.3) | 27 11.7 (3.0) | 0.5829 |

BCVA = best-corrected visual acuity; CI = confidence interval; ETDRS = Early Treatment Diabetic Retinopathy Score; SE = standard error of the mean.

a ANCOVA model, p value for treatment.effect